Stock ONC ONCOLYTICS BIOTECH INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Oncolytics Biotech Inc.

Equities

ONC

CA6823108759

Market Closed - Toronto S.E.
Other stock markets
 03:59:59 2024-04-22 pm EDT 		5-day change 1st Jan Change
1.46 CAD +1.39% Intraday chart for Oncolytics Biotech Inc. 0.00% -18.44%
Apr. 11 Oncolytics Biotech Inc. Announces the Submission of a Type C Meeting Request to the FDA CI
Apr. 11 Oncolytics Biotech Down 1.8% In US Premarket As Submits Type C Meeting Request to FDA MT

Evolution of the average Target Price on Oncolytics Biotech Inc.

Price target over the last 5 years

History of analyst recommendation changes

82f0522899b14.DEcZMvHsrYn1rzm1yd8szzdS1RfEZGy28YjiRMGS8Xw.QjFOVpmGmr6Fn1rCn5QYmmIbily3LTj0ldCHKIXrgQViFldnhJ_JzYbiSg~dca4d54808db9210ce372857323b9f7b

Analyst Recommendations on Oncolytics Biotech Inc.

HC Wainwright Adjusts Price Target on Oncolytics Biotech to $5 From $15, Maintains Buy Rating MT
Oncolytics Biotech Brief: Announcing Updated Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial that Show Pelareorep "Driving Robust Increases in Progression-Free Survival and Confirmed Overall Response Rate" MT
Oncolytics Biotech Inc. Announces Updated Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial That Show Pelareorep Driving Robust Increases in Progression-Free Survival and Confirmed Overall Response Rate CI
JonesTrading Initiates Oncolytics Biotech at Buy With $9 Price Target MT
Canaccord Genuity Adjusts Price Target on Oncolytics Biotech to $5 From $6, Maintains Buy Rating MT
Oncolytics Biotech Inc. Reports Interim Results from Phase 1/2 Goblet Study Showing A 70% Objective Response Rate in Pancreatic Cancer At the SITC Annual Meeting CI
Oncolytics Biotech Brief: Reporting Interim Results from Phase 1/2 GOBLET Study Showing a 70% Objective Response Rate in Pancreatic Cancer at the SITC Annual Meeting MT
Maxim Initiates Oncolytics Biotech With Buy Rating, Sets Price Target at $3 MT
RBC Capital Keeps OutperformSpeculative on Oncolytics Biotech MT
ONCOLYTICS BIOTECH : RBC Capital Keeps Outperform/Speculative Risk Rating, $6 TP on Oncolytics Biotech MT
ONCOLYTICS BIOTECH : HC Wainwright Starts Oncolytics Biotech at Buy With $15 Price Target MT
ONCOLYTICS BIOTECH : RBC Capital Keeps Outperform/Speculative Risk on Oncolytics Biotech After Q3 MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
1.46 CAD
Average target price
5.833 CAD
Spread / Average Target
+299.54%
High Price Target
8.5 CAD
Spread / Highest target
+482.19%
Low Price Target
3 CAD
Spread / Lowest Target
+105.48%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Oncolytics Biotech Inc.

HC Wainwright
JonesTrading Institutional Services
Canaccord Genuity
Maxim
RBC Capital Markets

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. ONC Stock
  4. Consensus Oncolytics Biotech Inc.